Hackensack, NJ – According to New Jersey Business Magazine, “Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center in Washington, and John Theurer Cancer Center, part of Hackensack University Medical Center in Hackensack, have announced that they have developed a joint cancer research agenda as part of a multi-year plan to form a National Cancer Institute (NCI) recognized cancer consortium. This recognition would support the scientific excellence of the two centers along with their capability to integrate multi-disciplinary, collaborative research approaches to focus on all the aspects of cancer.
|
0 Comments
Basking Ridge, NJ – According to New Jersey Business Magazine, Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen, announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for Dysport® (abobotulinumtoxinA) for the treatment of upper limb spasticity (ULS) in adult patients to decrease the severity of increased muscle tone in elbow flexors, wrist flexors and finger flexors. Clinical improvement may be expected one week after administration of Dysport®.”
New Brunswick, NJ - The HealthCare Institute of New Jersey (HINJ) applauds the U.S. House of Representatives’ passage of the 21st Century Cures Act. This landmark legislation would accelerate the pace of discovering new, life-saving treatments and cures for some of the world’s most dreaded diseases. It is vitally important to New Jersey’s life sciences community, where much of this research and discovery takes place, and it is critical to patients around the world who will benefit from its impact.
Trenton, NJ - According to Tom Bergeron of NJBiz, "Novartis officials were hoping the FDA would give approval for what they hope will be a blockbuster drug for heart failure by the end of the summer. On Tuesday, they got even better news. The U.S. Food & Drug Administration approved Entresto (formerly called LCZ696) six weeks ahead of the priority review action date."
New Brunswick, NJ - Rutgers University Cell and DNA Repository (RUCDR) Infinite Biologics , BioRealm, LLC, and – Affymetrix, Inc. announced a broad strategic alliance. This alliance will leverage BioRealm's SmokeScreen® platform to genotype the National Institute on Drug Abuse (NIDA) biorepository of more than 50,000 samples, collected from human subjects studied in NIDA-funded research. NIDA preserves these samples in a biorepository at RUCDR Infinite Biologics, on the campus of Rutgers University.
Ramsey, NJ - According to Eric Strauss of NJBiz, "Ramsey-based biopharmaceutical company ADMA Biologics Inc. has added a senior vice president and two other executives to its commercialization team as it prepares to seek a license for its top immune deficiency disease product."
Trenton, NJ - According to NJ Business magazine, "On June 30, the NJ Economic Development Authority (EDA) announced it is accepting applications for a second group of Executives-in-Residence at the Commercialization Center for Innovative Technologies (CCIT). The program, a joint effort organized by the EDA and BioNJ, links emerging biotechnology companies with experienced mentors to help take their businesses to the next level. Applications are open to New Jersey executives with experience in business development, health economics, regulation and other areas. More information can be found here.
Summit, NJ - Celgene Corporation announced that it has entered into an agreement to purchase the Merck & Co., Inc. research and office facility located at 556 Morris Avenue in Summit, New Jersey. Pending the completion of due diligence, closing is planned for September. Financial terms of the agreement are not being disclosed.
Princeton, NJ - According to John Greenwald of the Princeton Plasma Physics Laboratory, "What began as a chat between husband and wife has evolved into an intriguing scientific discovery. The results, published in May in BMJ (formerly British Medical Journal) Open, show a “highly significant” correlation between periodic solar storms and incidences of rheumatoid arthritis (RA) and giant cell arteritis (GCA), two potentially debilitating autoimmune diseases. The findings by a rare collaboration of physicists and medical researchers suggest a relationship between the solar outbursts and the incidence of these diseases that could lead to preventive measures if a causal link can be established."
Trenton, NJ – Enhancing the administration's firm commitment to finding new and innovative ways to help New Jersey families impacted by autism, First Lady Mary Pat Christie and Health Commissioner Mary E. O’Dowd today announced $4.4 million in grants to establish Autism Medical Homes and the advance research in the understanding, prevention, evaluation and treatment of the biologically-based disorder. New Jersey is a national leader in early intervention and education of children with autism which affects about 1 in 45 children across the Garden State.
Newark, NJ - Highlighting New Jersey’s leadership as a home for innovation and the “Medicine Chest of the World,” Lt. Governor Kim Guadagno addressed the New Jersey Performing Arts Center’s (NJPAC) Business Partners “Life Sciences as an Engine of Innovation” Roundtable, presented in association with the HealthCare Institute of New Jersey (HINJ).
Philadelphia, PA – The Biotechnology Industry Organization (BIO) released “Bioscience Economic Development in the States: Legislation and Job Creation Best Practices” today at the 2015 BIO International Convention. The Best Practices Guide is the bioscience industry’s leading comprehensive analysis of state legislative and regulatory initiatives in support of economic development.
Washington D.C. – According to Margaret Anderson of FasterCures, “FasterCures is excited to mark the launch of our new “Science of Patient Input” program – bridging our Value & Coverage, Patient-Centered Benefit-Risk Assessment, and TRAIN (The Research Acceleration and Innovation Network) efforts. The program concentrates our work to expand opportunities for patient perspectives to shape decision-making across the discovery-development-delivery cycle. Between our latest article in Science Translational Medicine, new video on the history of patient engagement, and recent Value & Coverage workshop, we’ve kicked things off with a bang."
Philadelphia, PA. – The Biotechnology Industry Organization (BIO) announced its selection of New Jersey State Assemblywoman Pamela Lampitt (6th District) as a state Legislator of the Year for 2015. Assemblywoman Lampitt is the prime sponsor of A-2477, which authorizes the prescription and dispensing of biosimilar products in New Jersey. Assemblywoman Lampitt received this honor during the 2015 BIO International Convention.
Trenton, NJ - According to BioNJ, "BioNJ President and CEO Debbie Hart, along with five other New Jersey executives, including Bob Hugin, Chairman and CEO, Celgene; Sol Barer, Ph.D., Founder, Celgene, and Managing Partner, SJ Barer Consulting; Robert Hariri, M.D., Ph.D., Chairman and Founder, Celgene Cellular Therapeutics; Paul Stoffels, M.D., CSO, Johnson & Johnson; and Shirley Tilghman, Ph.D., Professor, Molecular Biology, Princeton University, were named to the Worldview 100 as six of the 100 most influential people in biotechnology."
|
Do not miss a single innovative moment and sign up for our newsletter!
|
